Research programme: cancer immunotherapeutics - Surface Oncology

Drug Profile

Research programme: cancer immunotherapeutics - Surface Oncology

Alternative Names: SRF 231

Latest Information Update: 10 Jun 2017

Price : $50

At a glance

  • Originator Surface Oncology
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD47 antigen inhibitors; Immunomodulators; Nucleotidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Jun 2017 Surface Oncology in-licenses OmniRat®, OmniMouse® and OmniFlic® platforms technology from Ligand Pharmaceuticals
  • 08 Nov 2016 Surface Oncology plans clinical trial of SRF 231 for Cancer in 2017
  • 11 Jan 2016 Surface Oncology and Novartis agree to co-develop novel cancer immunotherapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top